Related references
Note: Only part of the references are listed.Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study
Neale D. Cohen et al.
INTERNAL MEDICINE JOURNAL (2019)
Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
Daisuke Matsutani et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction
Kim A. Connelly et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
Fumitaka Soga et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension
Robert Chilton et al.
DIABETES OBESITY & METABOLISM (2017)
EMPA-REG OUTCOME: The Cardiologist's Point of View
Son V. Pham et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes
Nadjib Hammoudi et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action
Eirini Lioudaki et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study
Ryotaro Bouchi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
Javad Habibi et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
Tim Heise et al.
CLINICAL THERAPEUTICS (2016)
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
Subodh Verma et al.
DIABETES CARE (2016)
Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis
Harindra Rajasekeran et al.
KIDNEY INTERNATIONAL (2016)
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Silvio E. Inzucchi et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Preventable Major Cardiovascular Events Associated With Uncontrolled Glucose, Blood Pressure, and Lipids and Active Smoking in Adults With Diabetes With and Without Cardiovascular Disease: A Contemporary Analysis
Gabriela Vazquez-Benitez et al.
DIABETES CARE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
Roberto M. Lang et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2015)
Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice
Yusuke Kashiwagi et al.
PLOS ONE (2015)
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
David Z. I. Cherney et al.
KIDNEY INTERNATIONAL (2014)
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Lars Ryden et al.
EUROPEAN HEART JOURNAL (2013)
2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Diabetic cardiomyopathy: Myth or reality?
Laura Ernande et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2012)
Independent Associations of Glucose Status and Arterial Stiffness With Left Ventricular Diastolic Dysfunction An 8-year follow-up of the Hoorn Study
Katja van den Hurk et al.
DIABETES CARE (2012)
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Jan Bolinder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
A new insight of mechanisms, diagnosis and treatment of diabetic cardiomyopathy
Xinli Zhang et al.
ENDOCRINE (2012)
Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice
Masayuki Suzuki et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Established and Novel Clinical Applications of Diastolic Function Assessment by Echocardiography
Jae K. Oh et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2011)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
Cardiovascular Outcomes in Framingham Participants With Diabetes The Importance of Blood Pressure
Guanmin Chen et al.
HYPERTENSION (2011)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
Changes in Diastolic Dysfunction in Diabetes Mellitus Over Time
Aaron M. From et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states
Sanjay K. Banerjee et al.
CARDIOVASCULAR RESEARCH (2009)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 diabetic patients
F González-Vílchez et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2005)
Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction - Results of the new York Heart Failure Registry
M Klapholz et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Medical progress: Heart failure
M Jessup et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Prevalence of left ventricular diastolic dysfunction in the community -: Results from a Doppler echocardiographic-based survey of a population sample
M Fischer et al.
EUROPEAN HEART JOURNAL (2003)
Share Paper
